Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-06-06
2006-06-06
Siew, Jeffrey (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S009100, C424S009340
Reexamination Certificate
active
07056506
ABSTRACT:
The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue.
REFERENCES:
patent: 5536814 (1996-07-01), Ruoslahti et al.
patent: 5567417 (1996-10-01), Sasisekharan et al.
patent: 5627263 (1997-05-01), Ruoslahti et al.
patent: 5677181 (1997-10-01), Parish
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5866540 (1999-02-01), Jonczyk et al.
patent: 5874081 (1999-02-01), Parish
patent: 5922676 (1999-07-01), Pasqualini et al.
patent: 6123941 (2000-09-01), Bissell
patent: 6177542 (2001-01-01), Ruoslahti et al.
patent: 6852318 (2005-02-01), Varner
patent: 0906919 (1999-04-01), None
patent: WO93/15203 (1993-08-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO96/04304 (1996-02-01), None
patent: WO 97/10507 (1997-03-01), None
patent: WO 97/33887 (1997-09-01), None
patent: WO 98/10795 (1998-03-01), None
patent: WO 99/13329 (1999-03-01), None
Schadendorf et al. (J. Pathol. 1993; 170: 429).
Mariani, G. et al. “Tumor Targeting Potential of the Monoclonal Antibody BC-1 against Oncofetal Fibronectin in Nude Mice Bearing Human Tumor Implants”,Cancer(1997)15:80(12 Suppl):2378-84.
Conforti, et al. “Human endothelial cells express integrin receptors on the luminal aspect of their membrane”,Blood(1992) 80(2):437-446.
Aota et al. (1994) “The Short Amino Acid Sequence Pro-His-Ser-Arg-Asn in Human Fibronectin Enhances Cell-adhesive Function,” J. Biol. Chem. 269:24756-24761.
Arap et al. (1998) “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model,” Science 279:377-380.
Bader et al. (1998) “Extensive Vasculogenesis, Angiogenesis, and Organogenesis Precede Lethality in Mice Lacking All αv Integrins,” Cell 95:507-519.
Bloch et al. (1997) “β1 Integrin is Essential for Teratoma Growth and Angiogenesis,” J. Cell Biol. 139:265-278.
Blystone et al. (1994) “Integrin αvβ3Differentially Regulates Adhesive and Phagocytic Functions of the Fibronectin Receptor α5β1,” J. Cell Biol. 127:1129-1137.
Brooks et al. (1994) “Requirement of Vascular Integrin αvβ3for Angiogenesis,” Science 264:569-571.
Brooks et al. (1994) “Integrin αvβ3Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels,” Cell 79:1157-1164.
Brooks et al. (1995) “Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin,” J. Clin. Invest. 96:1815-1822.
Carron et al. “A Peptidomimetic Antagonist of the Integrin αvβ3Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy,” Cancer Res. 58:1930-1935.
Castellani et al. (1994) “The Fibronectin Isoform Containing the Ed-B Oncofetal Domain: A Marker of Angiogenesis,” Int. J. Cancer 59:612-618.
Charo et al. (1990) “The Vitronectin Receptor αvβ3Binds Fibronectin and Acts in Concert with α5β1in Promoting Cellular Attachment and Spreading on Fibronectin,” J. Cell Biol. 111:2795-2800.
Christofidou-Solomidou et al. (1997) “Expression and Function of Endothelial Cell αv Integrin Receptors in Wound-Induced Human Angiogenesis in Human Skin/SCID Mice Chimeras,” Amer. J. Path. 151:975-983.
Clark et al. (1982) “Blood Vessel Fibronectin Increases in Conjunction with Endothelial Cell Proliferation and Capillary Ingrowth During Wound Healing,” J. Invest. Derma. 79:269-276.
Clark et al. (1996) “Transient Functional Expression of αvβ3 on Vascular Cells during Wound Repair,” Amer. J. Path. 148:1407-1421.
Collo and Pepper (1999) “Endothelial cell integrin α5β1 expression is modulated by cytokines and during migration in vitro,” J. Cell Sci. 112:569-578.
Drake et al. (1992) “Antibodies to β1-Integrins Cause Alterations of Aortic Vasculogenesis, In Vivo,” Dev. Dynamics 193:83-91.
Drake et al. (1995) “An antagonist of integrin αvβ3prevents maturation of blood vessels during embryonic neovascularization,” J. Cell Sci. 108:2655-2661.
Friedlander et al. (1995) “Definition of Two Angiogenic Pathways by Distinct αvIntegrins,” Science 270:15001502.
Friedlander et al. (1996) “Involvement of integrins αvβ3and αvβ5in ocular neovascular diseases,” Proc. Natl. Acad. Sci. USA 93:9764-9769.
George et al. (1993) “Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin,” Dev. 119:1079-1091.
Goh et al. (1997) “Mesodermal defects and cranial neural crest apoptosis in α5 integrin-null embros,” Dev. 124:4309-4319.
Lan et al. (1998) “Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis,” J. Cell Sci. 11:3621-3631.
Kaczmarek et al. (1994) “Distribution of Oncofetal Fibronectin Isoforms in Normal, Hyperplastic and Neoplastic Human Breast Tissues,” Int. J. Cancer 58:11-16.
Koivunen et al. (1993) “Selectionof Peptides Binding to the α5β1Integrin from Phage Display Library,” J. Biol. Chem. 268:20205-20210.
Koivunen et al. (1994) “Isolation of a Highly Specific Ligand for the α5β1Integrin from a Phage Display Library,” J. Cell Biol. 124:373-380.
Magnusson et al. (1998) “Fibronectin: Structure, Assembly, and Cardiovascular Implications,” Arterioscler. Thromb. Vasc. Biol. 18:1363-1370.
Neri et al. (1997) “Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform,” Nature Biotech. 15:1271-1275.
Pierschbacher et al. (1981) “Location of the Cell-Attachment Site in Fibronectin with Monoclonal Antibodies and Proteolytic Fragments of the Molecule,” Cell 26:259-267.
Pytela et al. (1985) “Identification and Isolation of a 140 kd Cell Surface Glycoprotein with Properties Expected of a Fibronectin Receptor,” Cell 40:191-198.
Ruoslahti et al. (1981) “Alignment of Biologically Active Domains in the Fibronectin Molecule,” J. Biol. Chem. 256:7277-7281.
Sechler et al. (1998) “Control of Cell Cycle Progression by Fibronectin Matrix Architecture,” J. Biol. Chem. 273:25533-25536.
Senger et al. (1996) “Stimulation of Endothelial Cell Migration by Vascular Permeability Factor
Fetterolf Brandon
Siew Jeffrey
The Regents of the University of California
Townsend and Townsend / and Crew LLP
LandOfFree
Methods for detecting and inhibiting angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for detecting and inhibiting angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for detecting and inhibiting angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3624111